Cargando…

Berberine attenuates hepatic oxidative stress in rats with non-alcoholic fatty liver disease via the Nrf2/ARE signalling pathway

The present study investigated the effects of berberine (BBR) on hepatic oxidative stress and the nuclear factor erythroid 2-related factor 2/antioxidant response element (Nrf2/ARE) signalling pathway in rats in which non-alcoholic fatty liver disease (NAFLD) was induced by a high-fat diet. Rats wer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deng, Yuanjun, Tang, Kairui, Chen, Runsen, Nie, Huan, Liang, Shu, Zhang, Jinwen, Zhang, Yupei, Yang, Qinhe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396022/ https://www.ncbi.nlm.nih.gov/pubmed/30867696 http://dx.doi.org/10.3892/etm.2019.7208

Ejemplares similares

Lipidomic Analysis of the Protective Effects of Shenling Baizhu San on Non-Alcoholic Fatty Liver Disease in Rats
por: Deng, Yuanjun, et al.
Publicado: (2019)

Prevention of Nonalcoholic Hepatic Steatosis by Shenling Baizhu Powder: Involvement of Adiponectin-Induced Inhibition of Hepatic SREBP-1c
por: Tang, Kairui, et al.
Publicado: (2020)

Effects of Shugan-Jianpi Recipe on the Expression of the p38 MAPK/NF-κB Signaling Pathway in the Hepatocytes of NAFLD Rats
por: Deng, Yuanjun, et al.
Publicado: (2018)

Chinese Herbal Medicine Formula Shenling Baizhu San Ameliorates High-Fat Diet-Induced NAFLD in Rats by Modulating Hepatic MicroRNA Expression Profiles
por: Pan, Maoxing, et al.
Publicado: (2019)

A network pharmacology‐based approach to explore the effects of Chaihu Shugan powder on a non‐alcoholic fatty liver rat model through nuclear receptors
por: Nie, Huan, et al.
Publicado: (2020)

The Potential Effect of Chinese Herbal Formula Hongqijiangzhi Fang in Improving NAFLD: Focusing on NLRP3 Inflammasome and Gut Microbiota
por: Liang, Shu, et al.
Publicado: (2018)

Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease
por: Yan, Hong-Mei, et al.
Publicado: (2015)

PGK1 Drives Hepatocellular Carcinoma Metastasis by Enhancing Metabolic Process
por: Xie, Huijun, et al.
Publicado: (2017)

Berberine in Non-Alcoholic Fatty Liver Disease—A Review
por: Koperska, Anna, et al.
Publicado: (2022)

Update on Berberine in Nonalcoholic Fatty Liver Disease
por: Liu, Yang, et al.
Publicado: (2013)

Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease
por: Zhao, Li, et al.
Publicado: (2017)

Berberine Attenuates Hyperglycemia by Inhibiting the Hepatic Glucagon Pathway in Diabetic Mice
por: Zhong, Ying, et al.
Publicado: (2020)

Anti-inflammatory activity of berberine in non-alcoholic fatty liver disease via the Angptl2 pathway
por: Lu, Zengsheng, et al.
Publicado: (2020)

Chaihu-Shugan-San Decoction Modulates Intestinal Microbe Dysbiosis and Alleviates Chronic Metabolic Inflammation in NAFLD Rats via the NLRP3 Inflammasome Pathway
por: Liang, Yinji, et al.
Publicado: (2018)

Betaine attenuates chronic alcohol-induced fatty liver by broadly regulating hepatic lipid metabolism
por: Yang, Wenjuan, et al.
Publicado: (2017)

The Potential Mechanisms of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease
por: Zhu, Xiaopeng, et al.
Publicado: (2016)

Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidation
por: Barbier-Torres, Lucía, et al.
Publicado: (2020)

Improving the ameliorative effects of berberine and curcumin combination via dextran-coated bilosomes on non-alcohol fatty liver disease in mice
por: Chen, Yi, et al.
Publicado: (2021)

Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease
por: Chang, Xinxia, et al.
Publicado: (2016)

Preclinical Evidence of Berberine on Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Animal Studies
por: Ren, Sichen, et al.
Publicado: (2021)

Inhibiting Ceramide Synthesis Attenuates Hepatic Steatosis and Fibrosis in Rats With Non-alcoholic Fatty Liver Disease
por: Jiang, Meng, et al.
Publicado: (2019)

The ultrasound‐guided attenuation parameter is useful in quantification of hepatic steatosis in non‐alcoholic fatty liver disease
por: Ogino, Yu, et al.
Publicado: (2021)

Probiotic Bifidobacterium lactis V9 attenuates hepatic steatosis and inflammation in rats with non-alcoholic fatty liver disease
por: Yan, Yan, et al.
Publicado: (2020)

Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways
por: Lee, Seung Min, et al.
Publicado: (2022)

Liquid Biopsy for the Diagnosis of Viral Hepatitis, Fatty Liver Steatosis, and Alcoholic Liver Diseases
por: Shabangu, Ciniso Sylvester, et al.
Publicado: (2020)

Relationship between Controlled Attenuation Parameter and Hepatic Steatosis as Assessed by Ultrasound in Alcoholic or Nonalcoholic Fatty Liver Disease
por: Ahn, Jem Ma, et al.
Publicado: (2016)

Phytosterol esters attenuate hepatic steatosis in rats with non-alcoholic fatty liver disease rats fed a high-fat diet
por: Song, Lihua, et al.
Publicado: (2017)

Combined Use of Bicyclol and Berberine Alleviates Mouse Nonalcoholic Fatty Liver Disease
por: Li, Hu, et al.
Publicado: (2022)

Berberrubine, a Main Metabolite of Berberine, Alleviates Non-Alcoholic Fatty Liver Disease via Modulating Glucose and Lipid Metabolism and Restoring Gut Microbiota
por: Yang, Sa, et al.
Publicado: (2022)

Berberine ameliorates nonalcoholic fatty liver disease by a global modulation of hepatic mRNA and lncRNA expression profiles
por: Yuan, Xinlu, et al.
Publicado: (2015)

Non‐alcoholic fatty liver disease in patients with autoimmune hepatitis
por: Takahashi, Atsushi, et al.
Publicado: (2018)

Complements are involved in alcoholic fatty liver disease, hepatitis and fibrosis
por: Lin, Cheng-Jie, et al.
Publicado: (2018)

Challenges in the hepatic histopathology in non-alcoholic fatty liver disease
por: Brunt, Elizabeth M, et al.
Publicado: (2017)

Non-Alcoholic Fatty Liver Disease and Extra-Hepatic Cancers
por: Sanna, Claudia, et al.
Publicado: (2016)

Corrigendum: Phytosterol esters attenuate hepatic steatosis in rats with non-alcoholic fatty liver disease rats fed a high-fat diet
por: Song, Lihua, et al.
Publicado: (2017)

Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”
por: Liu, Yuanbin, et al.
Publicado: (2023)

The Effect of Berberine on Lipid Profile, Liver Enzymes, and Fasting Blood Glucose in Patients with Non-alcoholic Fatty Liver Disease (NAFLD): A Randomized Controlled Trial
por: Nejati, Lida, et al.
Publicado: (2022)

Berberine attenuate staphylococcal enterotoxin B-mediated acute liver injury via regulating HDAC expression
por: Du, Jiying, et al.
Publicado: (2018)

The Therapeutic Effect of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis
por: Wei, Xiaoyun, et al.
Publicado: (2016)

Amelioration of Intestinal Barrier Dysfunction by Berberine in the Treatment of Nonalcoholic Fatty Liver Disease in Rats
por: Li, Donghao, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_89ivkmiklsff6tuvn5g23qf5qc